XML 20 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments (Tables)
9 Months Ended
Mar. 28, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments, Gain (Loss) [Table Text Block]
The following tables summarize the gains (losses) from hedging activities recognized in the Company's Condensed Consolidated Statements of Income:

 
Three Months Ended
Three Months Ended
 
March 28, 2020
March 30, 2019
 
Net Revenue
 
Cost of Goods Sold
 
Operating Expenses
 
Net Revenue
 
Cost of Goods Sold
 
Operating Expenses
 
(in thousands)
Income and expenses line items in which the effects of cash flow hedges are recorded
$
561,916

 
$
195,479

 
$
183,090

 
$
542,383

 
$
201,552

 
$
183,691

 
 
 
 
 
 
 
 
 
 
 
 
Gain (loss) on cash flow hedges:
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts:
 
 
 
 
 
 
 
 
 
 
 
Gain (loss) reclassified from accumulated other comprehensive income into income
$

 
$
76

 
$
(94
)
 
$
6

 
$
261

 
$
(79
)


 
Nine Months Ended
Nine Months Ended
 
March 28, 2020
March 30, 2019
 
Net Revenue
 
Cost of Goods Sold
 
Operating Expenses
 
Net Revenue
 
Cost of Goods Sold
 
Operating Expenses
 
(in thousands)
Income and expenses line items in which the effects of cash flow hedges are recorded
$
1,646,026

 
$
575,742

 
$
561,877

 
$
1,757,784

 
$
613,669

 
$
570,588

 
 
 
 
 
 
 
 
 
 
 
 
Gain (loss) on cash flow hedges:
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts:
 
 
 
 
 
 
 
 
 
 
 
Gain (loss) reclassified from accumulated other comprehensive income into income
$

 
$
206

 
$
(868
)
 
$
50

 
$
(335
)
 
$
(1,906
)


Available-for-sale investments [Table Text Block]
Fair values were as follows:
 
March 28, 2020
 
June 29, 2019
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
(in thousands)
Available-for-sale investments
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Certificates of deposit
$

 
$

 
$

 
$

 
$
1,000

 
$

 
$

 
$
1,000

Corporate debt securities
47,408

 
31

 
(330
)
 
47,109

 
140,031

 
68

 
(109
)
 
139,990

Total available-for-sale investments
$
47,408

 
$
31

 
$
(330
)
 
$
47,109

 
$
141,031

 
$
68

 
$
(109
)
 
$
140,990


Schedule of long-term debt [Table Text Block]
The following table summarizes the Company’s outstanding debt obligations:
 
March 28, 2020
 
June 29, 2019
 
(in thousands)
3.45% fixed rate notes due June 2027
$
500,000

 
$
500,000

3.375% fixed rate notes due March 2023
500,000

 
500,000

Total outstanding debt
1,000,000

 
1,000,000

Less: Reduction for unamortized discount and debt issuance costs
(6,337
)
 
(7,416
)
Total long-term debt
$
993,663

 
$
992,584


Financial Instruments [Text Block] FINANCIAL INSTRUMENTS

Short-term investments
Fair values were as follows:
 
March 28, 2020
 
June 29, 2019
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
(in thousands)
Available-for-sale investments
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Certificates of deposit
$

 
$

 
$

 
$

 
$
1,000

 
$

 
$

 
$
1,000

Corporate debt securities
47,408

 
31

 
(330
)
 
47,109

 
140,031

 
68

 
(109
)
 
139,990

Total available-for-sale investments
$
47,408

 
$
31

 
$
(330
)
 
$
47,109

 
$
141,031

 
$
68

 
$
(109
)
 
$
140,990



In the three and nine months ended March 28, 2020 and March 30, 2019, the Company did not recognize any impairment charges on short-term investments. All available-for-sale investments have maturity dates between April 6, 2020 and March 12, 2021.

The Company invests in various financial instruments including corporate debt securities, commercial paper, and certificates of deposit which include instruments issued or managed by industrial, financial, and utility institutions and U.S. Treasury securities which include U.S. government Treasury bills and Treasury notes.

Derivative instruments and hedging activities

The Company incurs expenditures denominated in non-U.S. currencies, primarily the Philippine Peso and the Thai Baht associated with the Company's manufacturing activities in the Philippines and Thailand, respectively, and the European Euro, Indian Rupee, Japanese Yen, Taiwan New Dollar, South Korean Won, Chinese Yuan and Canadian Dollar, for sales offices and research and development activities undertaken outside of the U.S.

The Company has established a program that primarily utilizes foreign currency forward contracts to offset the risks associated with the effects of certain foreign currency exposures. The Company does not use these foreign currency forward contracts for trading purposes.

Derivatives designated as cash flow hedging instruments

The Company designates certain forward contracts as hedging instruments pursuant to Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). As of March 28, 2020 and June 29, 2019, the notional amounts of the forward contracts the Company held to purchase international currencies were $41.4 million and $48.5 million, respectively. As of March 28, 2020 and June 29, 2019, the Company did not hold any forward contracts to sell international currencies.

Derivatives not designated as hedging instruments

As of March 28, 2020 and June 29, 2019, the notional amounts of the forward contracts the Company held to purchase international currencies were $39.7 million and $19.6 million, respectively, and the notional amounts of forward contracts the Company held to sell international currencies were $11.8 million and $21.1 million, respectively. The increase in forward contracts held to purchase international currencies from fiscal year 2019 to fiscal year 2020 was primarily due to the addition of operating lease liabilities, which were recorded on the Company’s Consolidated Balance Sheet upon adoption of the new lease accounting standard, Topic 842. The Company's foreign currency forward contract gains or losses included in the Condensed Consolidated Statements of Income were not material for the three and nine months ended March 28, 2020 and March 30, 2019, respectively.

Effect of hedge accounting on the Condensed Consolidated Statements of Income

The following tables summarize the gains (losses) from hedging activities recognized in the Company's Condensed Consolidated Statements of Income:

 
Three Months Ended
Three Months Ended
 
March 28, 2020
March 30, 2019
 
Net Revenue
 
Cost of Goods Sold
 
Operating Expenses
 
Net Revenue
 
Cost of Goods Sold
 
Operating Expenses
 
(in thousands)
Income and expenses line items in which the effects of cash flow hedges are recorded
$
561,916

 
$
195,479

 
$
183,090

 
$
542,383

 
$
201,552

 
$
183,691

 
 
 
 
 
 
 
 
 
 
 
 
Gain (loss) on cash flow hedges:
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts:
 
 
 
 
 
 
 
 
 
 
 
Gain (loss) reclassified from accumulated other comprehensive income into income
$

 
$
76

 
$
(94
)
 
$
6

 
$
261

 
$
(79
)


 
Nine Months Ended
Nine Months Ended
 
March 28, 2020
March 30, 2019
 
Net Revenue
 
Cost of Goods Sold
 
Operating Expenses
 
Net Revenue
 
Cost of Goods Sold
 
Operating Expenses
 
(in thousands)
Income and expenses line items in which the effects of cash flow hedges are recorded
$
1,646,026

 
$
575,742

 
$
561,877

 
$
1,757,784

 
$
613,669

 
$
570,588

 
 
 
 
 
 
 
 
 
 
 
 
Gain (loss) on cash flow hedges:
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts:
 
 
 
 
 
 
 
 
 
 
 
Gain (loss) reclassified from accumulated other comprehensive income into income
$

 
$
206

 
$
(868
)
 
$
50

 
$
(335
)
 
$
(1,906
)


Outstanding debt obligations

The following table summarizes the Company’s outstanding debt obligations:
 
March 28, 2020
 
June 29, 2019
 
(in thousands)
3.45% fixed rate notes due June 2027
$
500,000

 
$
500,000

3.375% fixed rate notes due March 2023
500,000

 
500,000

Total outstanding debt
1,000,000

 
1,000,000

Less: Reduction for unamortized discount and debt issuance costs
(6,337
)
 
(7,416
)
Total long-term debt
$
993,663

 
$
992,584



On June 15, 2017, the Company completed a public offering of $500 million aggregate principal amount of the Company's 3.45% senior unsecured and unsubordinated notes due in June 2027 (“2027 Notes”), with an effective interest rate of 3.5%. Interest on the 2027 Notes is payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2017. The net proceeds of this offering were approximately $495.2 million, after issuing at a discount and deducting paid expenses.

On November 21, 2013, the Company completed a public offering of $500 million aggregate principal amount of the Company’s 2.5% coupon senior unsecured and unsubordinated notes due in November 2018 (“2018 Notes”), with an effective interest rate of 2.6%. Interest on the 2018 Notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing on May 15, 2014. The net proceeds of this offering were approximately $494.5 million, after issuing at a discount and deducting paid expenses. In November of 2018, the Company repaid the entire $500 million in principal and any outstanding interest, related to these outstanding notes.

On March 18, 2013, the Company completed a public offering of $500 million aggregate principal amount of the Company’s 3.375% senior unsecured and unsubordinated notes due in March 2023 (“2023 Notes”), with an effective interest rate of 3.5%. Interest on the 2023 Notes is payable semi-annually in arrears on March 15 and September 15 of each year. The net proceeds of this offering were approximately $490.0 million, after issuing at a discount and deducting paid expenses.

The debt indentures that govern the 2027 Notes and the 2023 Notes include covenants that limit the Company's ability to grant liens on its facilities and to enter into sale and leaseback transactions, which could limit the Company's ability to secure additional debt funding in the future. In circumstances involving a change of control of the Company followed by a downgrade of the rating of the 2027 Notes or the 2023 Notes, the Company would be required to make an offer to repurchase the affected notes at a purchase price equal to 101% of the aggregate principal amount of such notes, plus accrued and unpaid interest.

The Company accounts for all the notes above based on their amortized cost. The discount and expenses are being amortized to Interest and other income (expense), net in the Condensed Consolidated Statements of Income over the life of the notes. The interest expense is recorded in Interest and other income (expense), net in the Condensed Consolidated Statements of Income. Amortized discount and expenses, as well as interest expense associated with the notes, were $8.9 million and $8.9 million during the three months ended March 28, 2020 and March 30, 2019, respectively. Amortized discount and expenses, as well as interest expense associated with the notes, were $26.7 million and $32.5 million, respectively, during the nine months ended March 28, 2020 and March 30, 2019.

The estimated fair value of the Company’s outstanding debt obligations was approximately $1.0 billion as of March 28, 2020. The estimated fair value of the debt is based primarily on observable market inputs and is a Level 2 measurement.

The Company recorded interest expense of $9.3 million and $9.3 million during the three months ended March 28, 2020, and March 30, 2019, respectively. The Company recorded interest expense of $27.9 million and $33.9 million during the nine months ended March 28, 2020, and March 30, 2019, respectively.

Other Financial Instruments
For the balance of the Company’s financial instruments, cash equivalents, accounts receivable, accounts payable and other accrued liabilities, the carrying amounts approximate fair value due to their short maturities.